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Abstract 
Background: Due to the ability of the 8-aminoquinolines (8AQs) to kill different stages of the malaria parasite, 
primaquine (PQ) and tafenoquine (TQ) are vital for causal prophylaxis and the eradication of erythrocytic Plasmodium 
sp. parasites. Recognizing the potential role of cytochrome (CYP) 450 2D6 in the metabolism and subsequent hepatic 
efficacy of 8-aminoquinolines, studies were designed to explore whether CYP2D-mediated metabolism was related to 
the ability of single-dose PQ and TQ to eliminate the asexual and sexual erythrocytic stages of Plasmodium berghei.
Methods: An IV P. berghei sporozoite murine challenge model was utilized to directly compare causal prophylactic 
and erythrocytic activity (asexual and sexual parasite stages) dose–response relationships in C57BL/6 wild-type (WT) 
mice and subsequently compare the erythrocytic activity of PQ and TQ in WT and CYP2D knock-out (KO) mice.
Results: Single-dose administration of either 25 mg/kg TQ or 40 mg/kg PQ eradicated the erythrocytic stages 
(asexual and sexual) of P. berghei in C57BL WT and CYP2D KO mice. In WT animals, the apparent elimination of hepatic 
infections occurs at lower doses of PQ than are required to eliminate erythrocytic infections. In contrast, the minimally 
effective dose of TQ needed to achieve causal prophylaxis and to eradicate erythrocytic parasites was analogous.
Conclusion: The genetic deletion of the CYP2D cluster does not affect the ability of PQ or TQ to eradicate the blood 
stages (asexual and sexual) of P. berghei after single-dose administration.
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Primaquine (PQ) continues to be an indispensable drug 
for radical cure and presumptive anti-relapse therapy 
(PART or terminal prophylaxis) of Plasmodium vivax and 
Plasmodium ovale infections, while serving as an alterna-
tive for primary prevention [1, 2]. PQ is active against the 
hepatic stages of all human malaria parasites and the only 
FDA-approved drug active against the dormant hypnozo-
ite stages of P. vivax and P. ovale [3]. While there is no 
clinical benefit to the patient, PQ can be used as a control 
measure to render Plasmodium falciparum sexual blood 
stages (gametocytes) non-infective to mosquitoes and, 
therefore, disrupt transmission [4].
Tafenoquine (TQ) is a long half-life PQ analog that 
eliminates both hepatic and erythrocytic stages of Plas-
modium sp. and is currently being developed by the U.S. 
Army for chemoprophylaxis of all malaria and by GlaxoS-
mithKline and Medicines for Malaria Venture for the rad-
ical cure of P. vivax. [5, 6] PQ and TQ are generally well 
tolerated, but there are known liabilities associated with 
hemolytic reactions in patients with glucose-6-phosphate 
dehydrogenase (G6PD) deficiencies [2, 6–10]. Patients 
should be tested for G6PD deficiency before the multi-
dose regimens of PQ are prescribed for radical cure, 
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terminal prophylaxis, or chemoprophylaxis. The WHO 
recommends a single administration of 0.25 mg base/kg 
PQ as a relatively well-tolerated (even in G6PD deficient 
individuals) gametocytocidal dose to inhibit the trans-
mission of P. falciparum malaria [4].
In addition to this potential liability leading to the need 
for G6PD testing prior to dosing, the concept of PQ and 
TQ as prodrugs in the context of causal prophylaxis and 
radical cure has introduced another layer of complexity 
with administration. Recent pre-clinical findings at the 
Walter Reed Army Institute of Research (WRAIR) have 
shown that PQ requires CYP2D-mediated metabolism 
for Plasmodium berghei causal prophylaxis in mice [11, 
12]. Tafenoquine was also shown to require CYP2D-
mediated metabolism for causal prophylactic activity 
in P. berghei-infected mice [13]. These findings have led 
some to suggest an 8-aminoquinoline class effect associ-
ated with CYP2D-mediated metabolism requirements 
for activity [14]. Given that nearly ten percent of certain 
populations are cytochrome P450 (CYP) 2D6 deficient 
[15], it is clinically important to investigate whether 
CYP2D-mediated metabolism is related to the ability of 
PQ and TQ to eradicate the asexual and sexual erythro-
cytic stages of Plasmodium sp.
To probe this relationship, an established murine P. 
berghei challenge model was utilized involving an intra-
venous (IV) P. berghei sporozoite inoculation on day 0 
that results in a hepatic infection followed by subsequent 
erythrocytic infection on day 3 [16, 17]. Vehicle control 
mice are generally deceased or euthanized due to mor-
bidity within a week. The utility of this model has also 
been demonstrated for non-8-aminoquinoline structural 
motifs [16]. As shown in Table  1, administering drugs 
days −1, 0, and/or +1 versus day +4 post infection allows 
for the direct comparison of hepatic causal prophylactic 
activity versus anti-erythrocytic activity within the same 
challenge model. The utilization of luciferase-express-
ing sporozoites from P. berghei-infected mosquitoes 
and an in vivo imaging system (IVIS) permits visualiza-
tion and quantitation of developing hepatic stages of P. 
berghei for the causal prophylactic assessment of drugs, 
while flow cytometry (parasitaemia) and microscopy 
(gametocytaemia) are used to assess erythrocytic infec-
tions. To assess the effect of CYP2D-mediated metabo-
lism on the ability of PQ or TQ to eradicate erythrocytic 
infections, C57BL wild-type (WT) mice were utilized 
along with knock-out (KO) mice purchased with the 
murine CYP2D gene cluster deleted and monitored para-
sitaemia and gametocytaemia [18].
Methods
Study drugs
Primaquine (WR002975) and tafenoquine (WR238605) 
were supplied by the Walter Reed Army Institute of 
Research (WRAIR) chemical repository. Primaquine 
(PQ) was supplied as the bisphosphate salt and tafeno-
quine (TQ) was supplied as the succinate salt. Dosing 
was calculated based on the milligram per kilogram (mg/
kg) body weight with respect to the molecular weight of 
the free base. The bulk drug of TQ used for the study was 
synthesized for the WRAIR by Ash Stevens, Inc. (Detroit, 
MI USA) with a purity of >98%. PQ was purchased from 
Sigma Aldrich (St. Louis, MO USA) with a purity of 
>98%.
Sporozoites and viability
Luciferase-expressing P. berghei (strain ANKA) sporo-
zoites [19] were obtained from laboratory-reared 
female Anopheles stephensi mosquitoes from the 
Department of Entomology, Walter Reed Army Insti-
tute of Research. The mosquitoes were maintained at 
18°C for 17–22 days after feeding on P. berghei malaria 
infected Swiss ICR mice. As the salivary glands were 
extracted from the malaria-infected mosquitoes, they 
were stored on ice in RPMI medium with 1% mouse 
serum. Sporozoites were recovered by the method of 
Ozaki [20]. To ensure the inoculated sporozoites were 
viable following the isolation procedure, they were 
stained with a vital dye containing fluorescein diace-
tate [50 mg/mL acetone; Sigma Aldrich (St. Louis, MO 
USA)] and ethidium bromide [20ug/mL in phosphate-
buffered saline; Sigma Aldrich (St. Louis, MO)] and 
counted in a haemocytometer. The viability of sporozo-
ites ranged from 87 to 100%.
Table 1 In vivo P. berghei intravenous (IV) sporozoite challenge causal prophylactic and erythrocytic models
a Day of drug administration relative to IV sporozoite inoculation (day 0). IVIS In vivo imaging system
b Animals are monitored for 30 days or recrudescence and subsequent euthanasia due to comorbidities
Model Causal prophylactic model Erythrocytic treatment model
Drug administration (day)a −1, 0, and/or +1 +4
Endpointb Hepatic and erythrocytic parasites (asexual parasitemia) Erythrocytic parasites: parasitemia (asexual), gametocytemia 
(sexual)
Technique IVIS (liver), flow cytometry (parasitemia) Flow cytometry (parasitemia) microscopy (gametocytemia)
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Animal housing
Male 8–12 week-old C57BL CYP2D KO mice, bred using 
the method Scheer and colleagues [18], were purchased 
from Taconic (Hudson, NY USA). Male 6–8  week-old 
C57BL/6 wild-type mice were purchased from Charles 
River Laboratories (shipped from Raleigh, NC USA). 
Upon arrival, all animals were acclimated for 7  days in 
quarantine. The animals were housed in a cage contained 
in a room with a temperature range of 64–79 °F, 34–68% 
relative humidity, and a 12 h light/dark cycle. Food and 
water were provided ad  libitum during quarantine and 
throughout the study. The animals were fed a standard 
rodent maintenance diet. The C57BL/6 WT and C57BL 
CYP2D KO mice were cautiously housed separately and 
identified with the appropriate cage cards. Extra care was 
taken to ensure there were no labelling errors associated 
with WT and KO mice.
Intravenous sporozoite inoculation
Sporozoites were rapidly isolated from the same batch of 
mosquitoes for a given experiment and administered to 
C57BL/6 wild-type (WT) and CYP2D knock-out (KO) 
mice the same morning to control for biological and 
time-dependent variability in sporozoite preparations. 
Each mouse was inoculated intravenously in the tail vein 
with 10,000 sporozoites suspended in 0.1 mL volume on 
day 0. The WT group was randomized separately from 
the KO group after sporozoite inoculation and prior to 
dosing with the test drugs or vehicle control. All animal 
studies were performed under IACUC-approved proto-
cols. All animal experiments were conducted in a facil-
ity accredited by the Association for the Assessment and 
Accreditation of Laboratory Animal Care, International, 
and in compliance with the Animal Welfare Act and 
other federal statutes and regulations relating to animals 
and experiments involving animals and adhere to the 
principles stated in the Guide for the Care and Use of 
Laboratory Animals (National Academy Press, 1996).
Genetic verification
Ear punch pathological samples were collected from a 
subset of WT and KO mice and stored in 70% ethanol 
at −80  °C for 12  h in preparation for shipment the fol-
lowing day. The samples were blinded with identification 
numbers and shipped with dry-ice overnight to Taconic, 
where the biopsies were transferred to a 96-well box and 
the DNA was extracted using the Qiagen Blood and Tis-
sue extraction Kit® (Hilden, Germany). After extraction, 
the DNA was evaluated using a spectrophotometer to 
determine the concentration and normalized to 10  ng/
µL. A master mix was prepared using reagents obtained 
through Qiagen, dNTPs, and the four primers from 
MWG Operon. The master mix was distributed into the 
PCR plate, and upon thermal cycling, the product was 
processed with a capillary electrophoresis instrument. 
Reagent, primer information, and assay data are available 
in the Additional file 1: Figures S1–S4.
Test agent administration
Drug substances were administered orally on days −1, 0, 
and/or +1 (causal prophylactic experiments) or on day 
4 (blood-stage experiments) with respect to sporozoite 
inoculation on day 0. Dosing calculations were based 
upon body weight measurements obtained on the day 
of dosing prior to preparing fresh stock solutions of the 
test compounds by grinding the needed quantity of drug 
in cold (4 °C) 0.5% (w/v) hydroxyethyl cellulose and 0.2% 
(v/v) Tween-80 (0.5% HECT) and diluting to the appro-
priate concentration. Drugs were ground using a ProSci-
entific 300D homogenizer (Oxford, CT) and the particle 
size was measured using a Horiba LA-950V2 particle size 
analyzer (West Chicago, IL). Oral doses were delivered 
via an intragastric feeder (18-gauge) to the designated 
recipient.
In vivo imaging system (IVIS)
In vivo imaging studies of bioluminescence activity from 
luciferase expressing P. berghei infected mice were per-
formed using a Perkin Elmer IVIS Spectrum (Hanover, 
MD). Mice were evaluated at 24 h post sporozoite inoc-
ulation to confirm a liver-stage malaria infection. Mice 
received 200  mg/kg luciferin (Gold Biotechnology, St. 
Louis, MO) intraperitoneally in a volume not to exceed 
200  µL. Five minutes post luciferin administration, the 
mice were anesthetized in a sleeping chamber with 
inhaled isoflurane. The mice were then positioned ventral 
side-up on the IVIS on a 37 °C platform. The mice con-
tinue to receive isoflurane through nose cone delivery. A 
camera exposure time of 5  min was utilized for the 24, 
48, and 72 h time points with f-stop = 1 and large bin-
ning setting. Quantitative analysis of bioluminescence 
emitted from whole bodies or region of intensity (ROI) 
were determined by measuring the luminescence signal 
intensity in photons/second using the ROI settings of the 
Living Image® 4.0 software. The ROI, which measure-
ments were expressed in total flux of photons, was set 
to measure the bioluminescence signal emitted in the 
abdominal area at the location of the liver (24 and 48 h) 
and/or whole body imaging at 72 h.
Flow cytometry (FCM)
Mice were analysed for asexual blood stage infections by 
determination of parasitaemia of tail blood samples (3 μL 
each) using a FC500 MPL flow cytometer (Beckman-
Coulter Co., CA USA), which conducts five-color analy-
sis from either single or dual laser excitation. Infected 
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erythrocytes, uninfected erythrocytes, and leukocytes 
were gated on logarithmic forward/side dot plots. 
Cells were analysed at an average rate of 2000–3000 
erythrocytes/s. Filters were placed before the green (FL-
1) and red (FL-2) photomultiplier tubes (PMTs) such that 
the green PMT registered fluorescence emission between 
520 and 555  nm, and the red PMT measured emission 
greater than 580 nm. 2–3 µL of blood from the mouse tail 
was collected directly into 0.3 mL of 1% heparinized iso-
tonic buffer (PBS saline). In this study, 1 mL 0.04% of glu-
taraldehyde was used for fixation and the samples were 
then incubated at 4 °C for 60 min. The cells were centri-
fuged at 450×g for 5 min. The supernatant was removed 
by aspiration and the cells were re-suspended in 0.5 mL 
PBS buffer supplemented with 0.25% (v/v) Triton X-100 
for 10  min incubation at room temperature. After cen-
trifugation, the permeabilized cells were re-suspended in 
0.5  mL of RNase at 1  mg/mL concentrations and incu-
bated for at least 2 h at 37 °C to ensure complete diges-
tion of reticulocytes. Plasmodium berghei infection in 
mice results in anaemia and subsequent reticulocytosis. 
Therefore, high RNAse concentrations for digesting large 
amounts of reticulocytes RNA were required for assess-
ment of parasitaemia in this mouse model. YOYO-1 dye 
(from 1  mM stock solution in DMSO) was diluted to 
2500 ng/mL (100-fold) concentrations in PBS and 20 µL 
of YOYO-1 solution at 2500 ng/mL was added to 0.5 mL 
of sample to a final dye concentration of 100  ng/mL of 
YOYO-1, which has been shown to be optimal to discrim-
inate infected erythrocytes from the lowest (0.01%) to the 
highest parasitaemia counts (74.0%) [21, 22]. It should be 
noted that tail blood flow cytometry measurements were 
performed on 10 naïve mice which all resulted in a back-
ground flow cytometry value of 0.3% parasitaemia. This 
background value was subtracted from the flow cytom-
etry values obtained for each animal during the study. All 
values in this manuscript reflect corrected flow parasitae-
mia with 0.3% background subtracted.
Slide preparation and light microscopy
With the mouse restrained, a needle was used to prick 
the tail vein and one drop of blood was massaged from 
the vein and directly placed on a 25 ×  75  mm micros-
copy slide (Fischer Scientific, USA) labelled with the 
date and animal ID number. A clean slide was used to 
“smear” the blood to create a single layer of erythrocytes/
reticulocytes with a “feathered-edge.” The thin smear 
was allowed to dry at ambient room temperature for 
4 h prior to fixing the slides with methanol. 20% Giemsa 
(Sigma Aldrich, USA) in phosphate buffer [10L batch: 
7  g potassium phosphate monobasic (Fischer Scientific, 
USA), 10 g sodium phosphate dibasic (Fischer Scientific, 
USA), 10L DI water] was utilized to stain the slides for 
30 min prior to rinsing with DI water. The stained slides 
were allowed to dry 12  h in ambient temperature prior 
to adhering cover slips (Fischer Scientific, USA) using 
Poly-Mount® (Polysciences Inc., Warrington, PA). The 
slides were randomly distributed to 4 microscopists 
who were provided guidelines for slide reading meth-
odology. Using a 100× high-power microscope, an eye-
piece graticule with a St Andrew’s cross, and a layer of 
immersion oil (Sigma Aldrich, USA), parasitized cells in 
ten fields were quantified to provide the mean cell per-
centages associated with the sexual and asexual stages of 
P. berghei [23–25]. Percent parasitaemia was calculated 
as [(mean number asexual parasites)/(mean number 
of total RBCs in one quadrant  ×  4)]  ×  100. The per-
cent gametocytaemia was calculated as [(mean number 
mature gametocytes)/(mean number of total RBCs in one 
quadrant × 4)] × 100.
Parasitemia correlation
The quantification of erythrocytic parasites was accom-
plished using flow cytometry (asexual stages) and 
microscopy (sexual and asexual parasites). The utiliza-
tion of flow cytometry allowed for the rapid determina-
tion of parasitaemia (asexual parasites) and the results 
are reflected in the tables and figures of the manuscript. 
Due to the meticulous nature of the microscopists, both 
sexual and asexual parasites were quantified. The per-
cent parasitaemia derived from microscopy and flow 
cytometry was subsequently utilized to correlate the two 
methods. The relationship between percent parasitaemia 
determined using flow cytometry versus light micros-
copy was performed using R version 3.2.4. Linear and 
non-linear relationships were analysed utilizing linear 
and polynomial regression as well as a repeated measures 
analysis with a spatial power law covariance structure to 
account for correlation between time points. The corre-
lation serves to link the parasite quantification derived 
from flow cytometry and microscopy. Correlation results 
are presented in the Additional file 1: Figure S7.
Pharmacokinetic parameter determination
Pharmacokinetic (PK) parameters for PQ and TQ in 
plasma and liver generated by the WRAIR [26, 27] were 
analysed using noncompartmental analysis (NCA) via 
the Phoenix-Win-Nonlin software package (version 6.4; 
Pharsight Corp., Mountain View, CA). The PK parame-
ters were utilized to explore the variability between wild-
type and CYP2D knock-out mice.
Statistical analysis
All tests of significance between groups across days 
were performed based on a linear regression model 
with repeated measures fit using a spatial power law 
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covariance matrix (similar to the AR(1) model but allow-
ing for unequally spaced days). All models included main 
effects for treatment group and study day, as well as a 
group × day interaction. When comparing mouse strains, 
the model also included a main effect for strain, the two-
way interactions with group and day, and the three-way 
group × day × strain interaction. Significance was based 
on the means from the interaction terms within day, and 
correction for multiple testing was based on Tukey’s post 
hoc correction for all pairwise tests. Correlation was ana-
lysed based on a simple linear regression model, polyno-
mial regression models up to third-degree polynomials, 
and a repeated measures model. A LOESS curve was also 
fit for comparison.
Graphical representations
Data analysis and graphical representations were gener-
ated using either Phoenix-Win-Nonlin software pack-
age (version 6.4; Pharsight Corp., Mountain View, CA), 
Microsoft Excel, and R version 3.2.4.
Results
C57BL/6 wild‑type (WT) murine causal prophylactic 
and treatment dose‑ranging studies
Single-dose primaquine (PQ) and tafenoquine (TQ) 
dose-ranging studies were completed in order to assess 
the dose–response relationships between causal pro-
phylactic (hepatic) activity and treatment (erythrocytic) 
activity and establish the dosing regimen for the CYP2D 
KO versus WT study erythrocytic study.
Primaquine causal prophylactic (hepatic) activity
PQ was administered for causal prophylaxis on either 
day 0 and/or day +1 relative to IV sporozoite inocula-
tion on day 0. Traditionally, the WRAIR administers 
drugs on days −1, 0, +1 to assess causal prophylactic 
activity in the IV sporozoite challenge model [16, 17]. 
Given the short half-life and rapid clearance of PQ in 
C57BL wild-type mice (plasma t1/2 =  1.5 ±  0.4  h; liver 
t1/2 =  3.6 ±  1.2  h [26]), it was predicted that adminis-
tering PQ on day −1 would not result in the clearance 
of hepatic parasites on day 0 and was not necessary for 
causal prophylaxis. This was confirmed when 25  mg/
kg of PQ was administered day 0 and day +1 leading 
to 100% suppression of the hepatic IVIS signal and no 
detected erythrocytic infection after 30 days post infec-
tion. Subsequently single-dose PQ (40, 20, or 10  mg/
kg) was administered day 0 relative to IV sporozoite 
inoculation. The 40 and 20  mg/kg cohorts led to 100% 
suppression of the hepatic IVIS signal and no detected 
erythrocytic infection. The 10 mg/kg cohort led to 100% 
suppression of the hepatic IVIS signal and no erythro-
cytic infection was detected in 3/5 mice. This suggests 
that hepatic parasites below the IVIS limit of detection 
exited the liver to infect the blood. The administration of 
40 mg/kg of PQ day +1 led to incomplete suppression of 
the hepatic IVIS signal and 0/5 animals free of parasitae-
mia (Table 2).
Primaquine erythrocytic treatment activity
Single-dose PQ (10, 20, and 40 mg/kg) was administered 
on day +4 relative to IV sporozoite inoculation and blood 
samples were analysed using flow cytometry and light 
microscopy to assess parasitaemia and gametocytaemia, 
respectively. PQ administration in each cohort led to 
the initial eradication of erythrocytic parasites followed 
by recrudescence observed on day 11. These suggest 
PQ eradicates hepatic infections at lower doses than are 
required to eliminate erythrocytic infections (Table 2).
Tafenoquine causal prophylactic (hepatic) activity 
and erythrocytic treatment activity
TQ exhibited comparable dose–response relationships 
for hepatic and erythrocytic reservoirs of parasitae-
mia in wild-type animals. As shown in Table 3, 20 mg/
kg TQ led to 100% suppression of the IVIS signal and 
no detectable erythrocytic infection for 5/5 mice when 
administered on days −1, 0, and/or +1, while lower 
doses led to either incomplete suppression of the IVIS 
signal or failure to eradicate the erythrocytic infections 
within the dosing cohorts. Given the long half-life of 
TQ in wild-type mice (plasma t1/2 = 53.8 ± 3.5 h; liver 
t1/2 = 83.5 ± 2.3 h [27]), the causal activity of TQ admin-
istered on day −1 is likely related to drug remaining in 
the liver when sporozoites are inoculated on day 0; the 
anti-erythrocytic activity in the absence of causal activ-
ity of TQ administered on day +1 could be related to 
drug remaining in the circulation when parasites emerge 
from the liver on day +3. The administration of 20 mpk 
day +4 led to the eradication of erythrocytic parasites in 
4/5 mice with recrudescence observed in 1/5 mice after 
29 days (Table 3).
Comparison of PQ or TQ in wild‑type (WT) and CYP2D 
knock‑out (KO) C57BL mice
The disease progression of P. berghei in both liver and 
blood was shown to be analogous in C57BL wild-type 
(WT) and CYP2D knock-out (KO) mice (refer to Addi-
tional file  1: Figure S3). Following IV sporozoite inocu-
lation (day 0), the presence of a liver stage infection was 
detected at 24 and 48  h followed by an erythrocytic 
infection at 72 h in both WT and CYP2D KO mice. The 
erythrocytic infection progressed analogously in WT and 
CYP2D KO vehicle control mice until mortality or eutha-
nasia due to morbidity occurred within approximately 
one week following infection.
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A single dose of drug was administered day +4 post 
infection to study the effect of CYP 2D-mediated 
metabolism relative to the ability of PQ and TQ to ini-
tially eradicate P. berghei erythrocytic stages (rather than 
determine the optimal dosing regimen to avoid recrudes-
cence). Blood samples were analysed using flow cytom-
etry (asexual stages) and light microscopy (sexual stages) 
to assess parasitaemia (Additional file  1: Figure S5) and 
gametocytaemia (mature gametocytes; Additional file 1: 
Figure S6), respectfully.
Single-dose PQ (40 mg/kg) and TQ (25 mg/kg) eradi-
cated erythrocytic parasites in both WT and CYP2D 
KO mice for one week post-drug administration. Recru-
descence was observed day 11 in the PQ-treated WT 
and CYP2D KO cohorts (Additional file  1: Figures 
S5 and S6), which corresponds to the short half-life 
Table 2 Primaquine (PQ) wild-type (WT) dose-ranging studies using C57BL/6 mice
PQ primaquine, mg/kg milligrams free base of drug per kg body weight, NA not applicable, IVIS in vivo imaging system
a Day of drug administration relative to intravenous sporozoite (IV SPZ) challenge (day 0) using C57BL/6 wild-type mice
b Number of animals without an IVIS signal (indicates no hepatic infection). D1 day 1 (relative to IV SPZ challenge day 0). D2 day 2 (relative to IV SPZ challenge day 0)
c Number of animals without parasitemia (flow cytometry) or gametocytemia (microscopy) day 29. N = 5 animals per cohort
Day dose administereda PQ dose (mg/kg) No hepatic IVIS signalb No asexual erythrocytic  
infection (parasitemia)c
No sexual erythrocytic 
infection (gametocytemia)c
Causal prophylactic model
 D0, D1 25 × 2d 5/5 (D1), 5/5 (D2) 5/5 NA
 D0 10 5/5 (D1), 5/5 (D2) 3/5 NA
20 5/5 (D1), 5/5 (D2) 5/5 NA
40 5/5 (D1), 5/5 (D2) 5/5 NA
 D1 40 1/5 (D1), 1/5 (D2) 0/5 NA
Erythrocytic treatment model
 D4 10 NA 0/5 0/5
20 NA 0/5 0/5
40 NA 0/5 0/5
Table 3 Tafenoquine (TQ) wild-type (WT) dose-ranging studies using C57BL/6 mice
TQ tafenoquine, mg/kg milligrams free base of drug per kg body weight, NA not applicable, IVIS in vivo imaging system
a Day of drug administration relative to intravenous sporozoite (IV SPZ) challenge (day 0) using C57BL/6 wild-type mice
b Number of animals without an IVIS signal (indicates no hepatic infection). D1 = day 1 (relative to IV SPZ challenge day 0). D2 = day 2 (relative to IV SPZ challenge 
day 0)
c Number of animals without parasitemia (flow cytometry) or gametocytemia (microscopy) day 29. N = 5 animals per cohort
Day dose administereda PQ dose (mg/kg) No hepatic IVIS signalb No asexual erythrocytic 
infection (parasitemia)c
No sexual erythrocytic 
infection (gametocytemia)c
Causal prophylactic model
 D1 2.5 0/5 (D1), 0/5 (D2) 0/5 NA
5 3/5 (D1), 2/5 (D2) 0/5 NA
10 5/5 (D1), 5/5 (D2) 4/5 NA
20 5/5 (D1), 5/5 (D2) 5/5 NA
 D0 2.5 0/5 (D1), 0/5 (D2) 0/5 NA
5 4/5 (D1), 4/5 (D2) 3/5 NA
10 3/5 (D1), 4/5 (D2) 2/5 NA
20 5/5 (D1), 5/5 (D2) 5/5 NA
 D1 20 0/5 (D1), 0/5 (D2) 5/5 NA
Erythrocytic treatment model
 D4 5 NA 0/5 0/5
10 NA 0/5 0/5
20 NA 4/5 4/5
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(WT t1/2 = 1.5 ± 0.4 h; CYP2D KO t1/2 3.5 ± 0.9 h) and 
rapid clearance of PQ in plasma [26]. Comparing CYP 
2D KO versus WT cohorts, no statistically significant 
differences in mean percent parasitaemia (Fig.  1) were 
observed for PQ until day 15, which resolved by day 25 
just prior to euthanasia. In regards to gametocytaemia, 
differences between PQ-treated WT and KO cohorts 
were not statistically significant except for day 11 (Fig. 2).
For 25  days following single-dose TQ administration, 
there was no statistical difference between WT and KO 
cohort mean parasitaemia (Fig. 1). There was no statisti-
cally significant difference relative to mean gametocytae-
mia (Fig.  2) between WT and KO cohorts treated with 
TQ for the duration of the study. The prolonged dura-
tion prior to recrudescence for the TQ-treated animals 
is likely related to the longer half-life in plasma (WT 
t1/2 = 53.8 ± 3.5 h; CYP2D KO t1/2 = 72.4 ± 15.5 h) and 
delayed clearance relative to PQ [27].
Pharmacokinetic‑pharmacodynamic (PK/PD) analysis
Figure  3 graphically annotates the plasma and liver 
fold-changes associated with 20 mg/kg PQ (Fig. 3a) and 
20 mg/kg TQ (Fig. 3b) CYP2D KO PK parameters versus 
reference (WT) strain parameters. A value of one repre-
sents no relative change in the PK parameter between the 
KO and WT mice (logarithmic x-axis).
Two items are noteworthy in regards to the fold-
changes representing the PK parameters of the parent 
compound: (1) In contrast to PQ, the mean PK parame-
ters for TQ generally reside toward the central line, which 
Fig. 1 Statistical comparison regarding differences in parasitemia between WT and CYP2D KO mice. The data were modeled using linear regression 
with repeated measures with a spatial power law covariance structure. The model included terms for study day, treatment group, mouse strain, and 
all interactions between the three terms. All point estimates, intervals, and p values therefore represent the differences within each day between 
mouse strains after adjusting for repeated measurements on the same mice. 40 mg/kg primaquine (PQ), 25 mg/kg tafenoquine (TQ), or vehicle 
control (VC) administered day 4 relative to intravenous sporozoite (IV SPZ) challenge (day 0) using C57BL/6 wild-type or C57BL/6 CYP2D knock-out 
mice. N = 10 animals per cohort. (Refer to Additional file 1: Figure S5 for percent parasitemia)
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indicates limited relative changes between CYP2D KO 
and WT mice treated with TQ and (2) both PQ and TQ 
single-dose administration eradicated erythrocytic para-
sites despite reduced clearance and increased exposure 
(AUC) of the parent compound in CYP2D KO mice com-
pared to WT mice. It is important to note that PQ par-
ent exposure is greatly increased in CYP2D KO vs WT 
mice, whereas TQ exposure is more modestly increased 
in CYP2D KO vs WT mice.
Discussion
Three key observations should be highlighted: (1) PQ erad-
icates hepatic parasites at lower doses than are required 
to eradicate erythrocytic parasites, while TQ exhibits an 
analogous dose–response relationship when comparing 
hepatic and erythrocytic activity, (2) there was no signifi-
cant difference between WT and CYP2D KO mice regard-
ing the preliminary eradication of erythrocytic parasites 
(asexual and sexual) following single-dose administra-
tion of both TQ (25  mg/kg) and PQ (40  mg/kg), and (3) 
the variability between WT and CYP2D KO murine PK 
parameters did not significantly affect the pharmacody-
namic endpoints of parasitaemia and gametocytaemia.
PQ is used as a causal prophylactic agent not a blood 
schizonticidal agent due to relatively greater activ-
ity against liver schizonts than blood schizonts [28–31] 
and in this P. berghei murine model, 20 mg/kg PQ caus-
ally protected all mice but led to recrudescence when 
used as a treatment for erythrocytic infection. It may be 
suggested that this comparability to clinical experience 
enhances the value of the P. berghei murine model and 
that it may be useful in screening new 8-aminoquinolines 
and novel drug classes in causal prophylactic and eryth-
rocyte treatment studies.
The somewhat lower prophylactic efficacy of PQ com-
pared to TQ after multiple administrations of both drugs 
has also been observed clinically. In a review, the efficacy 
of PQ (approximately 0.5 mg/kg/day from the day prior 
to parasite exposure until 1 week after parasite exposure) 
for P. falciparum ranged from 85 to 95% in five studies. 
Fig. 2 Statistical comparison regarding differences in gametocytemia between WT and CYP2D KO mice. The data were modeled using linear 
regression with repeated measures with a spatial power law covariance structure. The model included terms for study day, treatment group, mouse 
strain, and all interactions between the three terms. All point estimates, intervals, and p values therefore represent the differences within each day 
between mouse strains after adjusting for repeated measurements on the same mice. 40 mg/kg primaquine (PQ), 25 mg/kg tafenoquine (TQ), or 
vehicle control (VC) administered day 4 relative to intravenous sporozoite (IV SPZ) challenge (day 0) using C57BL/6 wild-type or C57BL/6 CYP2D 
knock-out mice. N = 10 animals per cohort. (Refer to Additional file 1: Figure S6 for gametocytemia)
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[1] In contrast, the efficacy of TQ (200 mg/day for 3 days 
as loading dose followed by 200 mg weekly) was 100% in 
non-immune Australian troops in comparison to meflo-
quine efficacy of 100% and placebo failure rate estimated 
at 8% [32]. TQ efficacy was 98% in semi-immune Afri-
cans where the efficacy of mefloquine was also 98% and 
the placebo failure rate was 32% [33]. This PQ versus TQ 
comparison supports the PQ hepatic versus erythrocytic 
infection comparison of the prior paragraph and again 
suggests that the P berghei mouse model may be reason-
ably comparable to the clinical situation.
If the P. berghei model has clinical relevance, our 
work suggests that CYP2D6 polymorphisms will not be 
important for TQ erythrocytic clinical activity. The lack 
of effect due to CYP2D-cluster deletion on TQ erythro-
cytic activity is in contrast to the previous demonstration 
of CYP2D-mediated activity relative to liver schizonts in 
mice [11, 13]. Since TQ prophylactic activity is thought 
to require some efficacy against blood-stage asexual par-
asites, the present work suggests that prospective human 
prophylactic candidates do not need to be screened for 
2D6 polymorphisms.
Given that CYP2D-mediated metabolism is required 
for causal prophylaxis and radical cure (in the case of 
primaquine) but not for the eradication of the erythro-
cytic parasites, it is reasonable to suppose that 8-ami-
noquinolines exhibit different modes of action against 
different stages of the parasite. Clearing parasites from 
hepatocytes may involve metabolic activation to oxida-
tive intermediates [11–13], which are produced at lower 
concentrations in CYP2D KO mice relative to WT mice 
[26, 27]. In the case of erythrocytic stages, inhibition of 
haematin agglutination has been proposed [34], although 
this leads to further questions regarding the mechanistic 
rational related to the pluripotentiality of 8-aminoquino-
lines and warrants further exploration.
Conclusion
Overall, this C57BL murine model mimics the clinical 
experience for PQ and TQ and may be useful in screen-
ing new 8-aminoquinolines and potentially novel drug 
classes to directly compare causal prophylactic and 
treatment dosing regimens. The model allowed for the 
direct comparison of causal prophylaxis and treatment 
modalities and indicates that PQ inhibits hepatic infec-
tions at lower doses than were required to treat eryth-
rocytic infections. In contrast, TQ exhibits analogous 
dose–response relationships relative to hepatic and 
erythrocytic infections in wild-type animals. In addi-
tion, TQ clears erythrocytic infections at lower doses 
than PQ. The data comparing wild-type and genetically-
modified mice suggest that single-dose administration 
of TQ and PQ are not impacted by CYP2D mediated 
Fig. 3 Relative fold changes of primaquine and tafenoquine CYP2D 
KO pharmacokinetic parameters from reference (WT parameters) 
in mouse plasma and liver. Indicated are the fold changes after the 
administration 20 mg/kg primaquine (PQ) and 20 mg/kg tafenoquine 
(TQ) in the CYP2D KO strain as compared to WT C57BL/6 mice. The fold 
change is indicated by the x-axis and the pharmacokinetic parameter 
on the y-axis. A value of one represents no relative change in the 
pharmacokinetic parameter between the KO and WT mice. The grey 
bars are provided for visual reference. The error shown is the standard 
deviation of relative fold changes for KO pharmacokinetic parameters 
as compared to WT means pharmacokinetic parameter values. PQ and 
TQ comparisons were conducted using experimental data generated 
at the WRAIR [26, 27]. WT C57BL/6 wild-type mice. CYP2D KO C57BL 
CYP2D6 knock-out mice. MRT mean resonance time. CL/F apparent 
total clearance of the drug from plasma after oral administration. Vz/F 
apparent volume of distribution during terminal phase after non-
intravenous administration. AUCinf area under the plasma concen-
tration-time curve from time zero to infinity. AUClast area under the 
plasma concentration-time curve from time zero to the time of last 
measurable concentration. Cmax: maximum (peak) plasma drug con-
centration. Tmax time to reachmaximum (peak) plasma concentration 
following drug administration. T1/2 elimination half-life
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metabolism relative to the initial clearing of erythro-
cytic P. berghei infections to the same extent as hepatic 
infections.
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